Judicial Intervention in Rare Disease Management: Assessing the State’s Welfare Obligations
GS2GS4
The Supreme Court has taken suo motu cognizance of the systemic gaps in accessing treatment for Spinal Muscular Atrophy, emphasizing the constitutional mandate for equitable healthcare.
The Supreme Court’s recent decision to initiate suo motu proceedings regarding the treatment of patients suffering from Spinal Muscular Atrophy (SMA) marks a critical juncture in the discourse on the right to health within India’s constitutional framework. SMA, a rare and debilitating genetic disorder, requires prohibitively expensive lifelong treatments, often placing it outside the reach of the average citizen. By bringing this issue under its judicial scanner, the Court is effectively challenging the current limits of the state’s welfare-based healthcare delivery model.
At the heart of the matter lies the tension between budgetary constraints and the state’s ethical obligation toward the most vulnerable sections of society. The proposal for a corpus fund to support SMA patients mirrors broader debates on ‘orphan drugs’ and the state’s duty to ensure that life-saving interventions are not governed solely by market forces or private affordability. From a governance perspective, this highlights the necessity of institutionalized support mechanisms that go beyond reactive litigation, demanding proactive policy formulation under the Right to Life as enshrined in Article 21.
Continue reading — free with login
JeetoBharat publishes daily UPSC current affairs mapped to the Mains syllabus. Log in to read full articles.
Log in to read full articleNo credit card required. Free registered users get unlimited access.
This article was curated using AI. While we strive for accuracy, please verify critical facts from official sources.